The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma
Open accessAbstract
BACKGROUND: New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and pleural effusions could meet sensitivity and specificity criteria for a robust biomarker. METHODS: We measured fibulin-3 levels in plasma (from 92 patients with mesothelioma, 136 asbestos-exposed persons without cancer, 93 patients with effusions not due to mesothelioma, and 43 healthy controls), effusions (from 74 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not due to mesothelioma), or both. A blinded validation was subsequently performed. Tumor tissue was examined for fibulin-3 by immunohistochemical analysis, and levels of fibulin-3 in plasma and effusions were measured with an enzyme-linked immunosorbent assay. RESULTS: Plasma fibulin-3 levels did not vary according to age, sex, duration of asbestos exposure, or degree of radiographic changes and were significantly higher in patients with pleural mesothelioma (105±7 ng per milliliter in the Detroit cohort and 113±8 ng per milliliter in the New York cohort) than in asbestos-exposed persons without mesothelioma (14±1 ng per milliliter and 24±1 ng per milliliter, respectively; P<0.001). Effusion fibulin-3 levels were significantly higher in patients with pleural mesothelioma (694±37 ng per milliliter in the Detroit cohort and 636±92 ng per milliliter in the New York cohort) than in patients with effusions not due to mesothelioma (212±25 and 151±23 ng per milliliter, respectively; P<0.001). Fibulin-3 preferentially stained tumor cells in 26 of 26 samples. In an overall comparison of patients with and those without mesothelioma, the receiver-operating-characteristic curve for plasma fibulin-3 levels had a sensitivity of 96.7% and a specificity of 95.5% at a cutoff value of 52.8 ng of fibulin-3 per milliliter. In a comparison of patients with early-stage mesothelioma with asbestos-exposed persons, the sensitivity was 100% and the specificity was 94.1% at a cutoff value of 46.0 ng of fibulin-3 per milliliter. Blinded validation revealed an area under the curve of 0.87 for plasma specimens from 96 asbestos-exposed persons as compared with 48 patients with mesothelioma. CONCLUSIONS: Plasma fibulin-3 levels can distinguish healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions. (Funded by the Early Detection Research Network, National Institutes of Health, and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Basic principles of ROC analysis
Metz, C. E. (1978) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(78)80014-2 · Cited by 6,026
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma
(1995) · Chest · doi:10.1378/chest.108.4.1122 · Cited by 606
Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels
Pass, H. I., Lott, D., Lonardo, F., Harbut, M., Liu, Z., Tang, N., Carbone, M., Webb, C., & Wali, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051185 · Cited by 357
Self-citationA Comparative Analysis of the Fibulin Protein Family
Kobayashi, N., Kostka, G., Garbe, J. H. O., Keene, D. R., Bächinger, H. P., Hanisch, F.-G., Markova, D., Tsuda, T., Timpl, R., Chu, M.-L., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611029200 · Cited by 270
Hollevoet, K., Reitsma, J. B., Creaney, J., Grigoriu, B. D., Robinson, B. W., Scherpereel, A., Cristaudo, A., Pass, H. I., Nackaerts, K., Rodríguez Portal, J. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6671 · Cited by 230
Self-citationFibulins 3 and 5 Antagonize Tumor Angiogenesis In vivo
Albig, A. R., Neil, J. R., & Schiemann, W. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4096 · Cited by 163
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
Hu, B., Rajamani, K. T., Sim, H., & Viapiano, M. S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0207 · Cited by 135
Cited by
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
Malignant pleural effusion: from bench to bedside
Psallidas, I., Kalomenidis, I., Porcel, J. M., Robinson, B. W., & Stathopoulos, G. T. (2016) · European Respiratory Review · doi:10.1183/16000617.0019-2016 · Cited by 294
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
Røe, O. D., & Stella, G. M. (2015) · European Respiratory Review · doi:10.1183/09059180.00007014 · Cited by 185
Malignant mesothelioma as an oxidative stress-induced cancer: An update
Chew, S. H., & Toyokuni, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.002 · Cited by 102
Metadata
- Authors
- Pass, H. I., Levin, S. M., Harbut, M. R., Melamed, J., Chiriboga, L., Donington, J., Huflejt, M., Carbone, M., Chia, D., Goodglick, L., Goodman, G. E., Thornquist, M. D., Liu, G., de Perrot, M., Tsao, M.-S., & Goparaju, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-11
- Volume
- 367
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164503858
- Cited by
- 283
- References
- 28
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. https://app.cochat.ai/papers/10.1056/nejmoa1115050
- The paper
- Pass, H. I., Levin, S. M., Harbut, M. R., Melamed, J., Chiriboga, L., Donington, J., Huflejt, M., Carbone, M., Chia, D., Goodglick, L., Goodman, G. E., Thornquist, M. D., Liu, G., de Perrot, M., Tsao, M.-S., & Goparaju, C. (2012). Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1115050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.